Member Info for JoeyDiamond

Using a multiscale mathematical model...

In the machine-learning model...

Just to creating headlines/salespitch

As for the direction and future of SNG001 we are reliant on the data from the UNIVERSAL trial as it wasn't captured during Sprinter.

Latest update in Dec 23 was the trial had recruited 50% of participants. Timeline view they not as far progressed as hoped hence lack of updates from Synairgen.

P2 trial design and cohort is reliant on what UNIVERSAL tells us.

Can SNG001 cure long covid?

Answer = no

Luciferase reporter assays

https://www.promega.co.uk/products/luciferase-assays/reporter-assays/

Enzyme-linked immunosorbent assay (ELISA)

https://www.immunology.org/public-information/bitesized-immunology/experimental-techniques/enzyme-linked-immunosorbent-assay#:~:text=The%20enzyme%2Dlinked%20immunosorbent%20assay,in%20cell%20supernatant%20or%20serum.

These were the Assays used

Are they taking blood /serum samples in UNIVERSAL? If so you can test for the auto-abs.

One of the major criticisms of Sprinter was the failure of SNG to take samples (despite it being in the trial protocol) and meaning we couldnt test for auto-abs.

Https://www.theguardian.com/world/2023/aug/10/cyprus-begins-treating-islands-sick-cats-with-anti-covid-pills

Molnupirivir unused stockpiles that can no longer be used in humans as they were deauthorised are to be given to cats. A dangerous mutagenic drug that spawns new variants of a virus what can go wrong?

For anyone still interested in the molnupirivir story/scandal this forum tracked for a long time

Https://www.science.org/doi/10.1126/sciimmunol.adg0033

Nessab pretty interesting paper deserve it own little thread.

Key finding in here which could be relevent to SNGs research

Interesting I just checked the same website URL and the analysts 12-Month Price Target is a buy

Estimate is average 40.00 (+346.93% Upside)

I think you are reading it wrong Andy

https://uk.investing.com/equities/synairgen-plc-consensus-estimates

Nice to finally know the plan and the company position.

Cash position fine as expected.

No platform trial despite SNG being hawked round the shop window. Still a very slim chance it could happen but as RNS says the political will and cash is no longer there.

Going to have multiple exploratory trials in different target groups to see if we get a strong signal of efficacy which is welcome. No mention of AABs group of people which is disappointing.

Need to raise funds for a P3 trial if we get a strong signal in one of the exploratory trials.

So looking at 18 months minimum b4 a chance of a P3 trial imo.

After Sprinter I am disappointed we didnt start working toward these exploratory trials a year ago. It was obvious SNG would be a hard sell for any platform trial so there should have been a parallel plan in place back then! I feel a bit of a wasted year and some naivety from the leadership in waiting for 3rd party support.

Long hold again for me. I'm sure SNG will get another chance at a P3 :)

Hemo went down from 15p highs and recently down to 1p due to funding issues. Was focusing on CAR-T last time I checked but other larger pharma companies are more advanced in that space.

Has someone really suggested SNG need to rerun a phase 1 trial :)

A trial that mainly focuses on drug safety signals and side effects. Wow.

I think u miss the point on Paxlovid. Phizer + FDA wouldn’t release the full data on the drug and approval process until now. We now know why as for vaxxed non risk people there is no benefit.

In USA at least, the drug at $500 a pop has been given to anybody even without a positive Covid test! Phizer have made a fortune selling this drug in the knowledge it has no benefit to most people. What’s worse is FDA knew too and went along with it. The drug should only have been used in high risk populations.

The problem we have is the regulators are part funded by the big pharma companies they are meant to regulate. Complete conflict of interest.

The problem for SNG and indeed other smaller companies is even with a good drug the regulator is influenced by big pharma who will make it difficult for any competitors.

Going forward I think SNG will need to go a JV route with a bigger pharma company who have influence.

Only now

https://mobile.twitter.com/boulware_dr/status/1636156368599015425

Interesting thread on the new data finally released and how Paxlovid is beneficial to only high risk groups.

Andy u have previously told this board cash runway was til march 23, then June 23 now dec 23. You don’t seem confident with your numbers.

Could you give some facts from the actual SNG accounts to support your claim as to why a company with no current commercialisation or trial expenses would run out of money so soon?

https://mobile.twitter.com/janemerrick23/status/1628808024428056578

Sufficient worry now that UKHSA is considering introducing lateral flow tests to detect bird flu in people.

https://mobile.twitter.com/thijskuiken/status/1628786923794837507

Story to keep an eye on. After we have seen bird flu transmit into various mammals there is a worry this highly pathogenic strain may gain the ability to more freely transmit to humans.

Or for normal people, someone has sold £5,000 worth of shares.

But shares dumped, bigger balls, costly mistake makes it far more dramatic for sure.

One positive note is NIAID have amended this trial design to exclude some corticosteroids as they are well aware of the negative drug interactions they have to anti-virals.

So if SNG001 ever did make another trial we may be afforded the same exclusion.

In this trial it suggests the stronger more systemic corticosteroids are not permitted. They are generally used in hospital for inpatients, but disease course determines when to administer.

As S-217622 is an anti-viral it would be expected any systemic corticosteroids would dampen any anti viral effects and have negative impact to efficacy. So think they learnt a lesson here from a certain other P3 trial :)

Drugs like inhaled budesonide are permitted in this trial, a weaker steroid. So be interesting to see if there is much impact from these.

The sprinter trial was given an estimated 90% chance at launch to be adequately powered with the numbers recruited. At the time seemed an acceptable risk for costs/time saved when we had such strong P2 results.

https://mobile.twitter.com/yunlong_cao/status/1607915567696203776

New variant in China the cause

The superior growth advantage of XBB.1.5 has been well-documented by many colleagues.

Here I'll add some experimental data:
1) XBB.1.5 is equally immune evasive as XBB.1, but
2) XBB.1.5 has a much higher hACE2 binding affinity